Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + danburstotug complex AP160
- Development stage
- Discontinued
- Lead developer
- Mayo Clinic
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
nab-paclitaxel + danburstotug complex AP160 is an investigational antibody-drug conjugate (ADC) composed of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) combined with a monoclonal antibody targeting PD-L1 (danburstotug, also known as STI-3031). Nab-paclitaxel is a protein-bound formulation of the taxane paclitaxel that acts as an antimicrotubule agent by stabilizing microtubules and inhibiting their normal dynamic reorganization during cell division. Danburstotug targets programmed death-ligand 1 (PD-L1), potentially enhancing immune-mediated tumor cell killing through checkpoint inhibition and antibody-dependent cellular cytotoxicity. The combination aims to deliver both cytotoxic chemotherapy and immunotherapy in a single agent for improved antitumor activity. The primary indication under investigation has been advanced or metastatic solid tumors[6][8].
- Other names
- nab-paclitaxel/danburstotug complex AP160nab-paclitaxel/STI-3031 complexAP160AP-160AP 160
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + danburstotug complex AP160.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + danburstotug complex AP160.